Data for the paper - Use of Saccharomyces Boulardii CNCM I-745 as possible therapeutic strategy for prevention of nonsteroidal anti-inflammatory drug-induced intestinal injury

Published: 30 June 2022| Version 1 | DOI: 10.17632/g286rhxzjm.1
Vanessa D'Antongiovanni, Luca Antonioli, Laura Benvenuti, Carolina Pellegrini, Clelia Di Salvo, Marco Calvigioni, Adelaide Panattoni, Larisa Ryskalin, Gianfranco Natale, Sebastiano Banni, Gianfranca Carta, Emilia Ghelardi, Matteo Fornai


Objective: The use of nonsteroidal anti-inflammatory drugs (NSAIDs) can be associated with severe adverse digestive effects. The aim of this study was to examine the protective effects of the probiotic S. boulardii CNCM I-745 in a rat model of diclofenac-induced enteropathy. Design: Enteropathy was induced in 40-wk-old male rats by intragastric diclofenac (4 mg/kg BID for 14 days). S. boulardii CNCM I-745 (3 g/kg BID by oral gavage) was administered starting 14 days before (preventive protocol) or in concomitance (curative protocol) with diclofenac administration. Ileal damage, inflammation, barrier integrity, gut microbiota composition, and TLRs-NF-kB-pathway were evaluated. Results: Diclofenac elicited intestinal damage, along with increments of myeloperoxidase, malondialdehyde, tumor necrosis factor and interleukin-1β, overexpression of TLR-2/-4, MyD88, and NF-kB p65, increased faecal calprotectin and butyrate levels as well as a decrease in blood hemoglobin levels, occludin and butyrate transporter MCT1 expression. In addition, diclofenac provoked a shift of bacterial taxa in both faecal and ileal samples. Treatment with S. boulardii CNCM I-745, in both preventive and curative protocol, counteracted the majority of these deleterious changes. Only preventive administration of the probiotic counteracted NSAID-induced decreased expression of MCT1 and increase in faecal butyrate levels. No significant changes were observed for the occludin expression after probiotic treatment. Conclusion: Treatment with S. boulardii CNCM I-745 prevents diclofenac-induced enteropathy through anti-inflammatory and antioxidant activities. Such effects are likely to be related to increased tissue butyrate bioavailability, through an improvement of butyrate uptake by the enteric mucosa.



Universita degli Studi di Cagliari, Universita degli Studi di Pisa


Probiotics, Microbiota, Nonsteroidal Antiinflammatory Drugs, Preclinical Study